CR20230192A - Formulación sólida - Google Patents

Formulación sólida

Info

Publication number
CR20230192A
CR20230192A CR20230192A CR20230192A CR20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A
Authority
CR
Costa Rica
Prior art keywords
solid formulation
viral replication
pharmaceutical formulations
active pharmaceutical
pharmaceutical ingredient
Prior art date
Application number
CR20230192A
Other languages
English (en)
Inventor
Ivan Henri M Somers
Matthieu Jean M Ravelingien
Kristof Leonard Kimpe
Donghua Zhu
Sune Klint Andersen
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CR20230192A publication Critical patent/CR20230192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con formulaciones farmacéuticas que comprenden un ingrediente farmacéutico activo; y uno o una combinación de copolímero de ácido metacrílico, o un derivado de celulosa en donde el ingrediente farmacéutico activo es un inhibidor de la replicación viral del dengue. También se describen formas de dosificación sólidas que comprenden dichas formulaciones farmacéuticas, procesos para prepararlas y su uso en métodos de prevención y/o tratamiento y/o inhibición de la replicación viral.
CR20230192A 2020-11-04 2021-11-03 Formulación sólida CR20230192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/126596 WO2022094816A1 (en) 2020-11-04 2020-11-04 Solid formulation
PCT/CN2021/128521 WO2022095913A1 (en) 2020-11-04 2021-11-03 Solid formulation

Publications (1)

Publication Number Publication Date
CR20230192A true CR20230192A (es) 2023-10-26

Family

ID=78649077

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230192A CR20230192A (es) 2020-11-04 2021-11-03 Formulación sólida

Country Status (17)

Country Link
US (1) US20240000749A1 (es)
EP (1) EP4240331B1 (es)
JP (1) JP2023548348A (es)
KR (1) KR20230104226A (es)
CN (1) CN116685317A (es)
AU (1) AU2021376584A1 (es)
CA (1) CA3200538A1 (es)
CO (1) CO2023005726A2 (es)
CR (1) CR20230192A (es)
DO (1) DOP2023000084A (es)
MA (1) MA62094B1 (es)
MX (1) MX2023005219A (es)
PE (1) PE20231946A1 (es)
RS (1) RS68223B1 (es)
TW (1) TWI923631B (es)
UY (1) UY39503A (es)
WO (2) WO2022094816A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428307A (zh) * 2022-10-12 2024-07-16 日商中外製藥股份有限公司 包含胜肽、界面活性劑及聚合物的組成物
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
WO2026018176A1 (en) 2024-07-17 2026-01-22 Janssen Pharmaceuticals, Inc. 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118587A1 (en) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
WO2011080716A2 (en) * 2010-01-04 2011-07-07 Wockhardt Limited Pharmaceutical composition for modified delivery of actives
MX364946B (es) * 2012-04-04 2019-05-15 Vaxform Llc Sistema adyuvante mejorado para la administración de vacunas orales.
CA2893318A1 (en) * 2012-12-07 2014-06-12 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
CN113209024A (zh) * 2013-12-31 2021-08-06 阿森迪亚制药有限责任公司 疏水性化合物的药物组合物
JP6630887B2 (ja) * 2014-06-13 2020-01-15 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス複製阻害剤
MX2017011469A (es) * 2015-03-10 2018-01-23 Shionogi Inc Dispersiones sólidas.
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN105168166A (zh) * 2015-09-08 2015-12-23 深圳信立泰药业股份有限公司 用于治疗心血管疾病固体制剂的包衣技术
EP3305289A1 (en) * 2016-10-06 2018-04-11 Philipps-Universität Marburg Usage of silvestrol, episilvestrol and silvestrol analoga for the treatment of viral infections caused by viruses with cap-dependent translation
WO2018213365A1 (en) * 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
CA3075729A1 (en) * 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
IL316312A (en) * 2017-12-07 2024-12-01 Merck Sharp ַ& Dohme Llc Dengue virus vaccine compound formulations
US20190365738A1 (en) * 2018-05-21 2019-12-05 Cadila Healthcare Limited Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
BR112021004931A2 (pt) * 2018-09-18 2021-06-01 Metacrine, Inc. formas cristalinas de um agonista de receptor farnesoide x
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
CN111407728B (zh) * 2020-04-16 2022-02-22 重庆市畜牧科学院 一种替米考星肠溶性固体分散体及其制备方法和应用

Also Published As

Publication number Publication date
EP4240331A1 (en) 2023-09-13
RS68223B1 (en) 2026-07-31
CN116685317A (zh) 2023-09-01
MA62094B1 (fr) 2026-06-30
WO2022095913A1 (en) 2022-05-12
DOP2023000084A (es) 2023-11-15
PE20231946A1 (es) 2023-12-05
TWI923631B (zh) 2026-05-01
EP4240331C0 (en) 2026-04-29
US20240000749A1 (en) 2024-01-04
CO2023005726A2 (es) 2023-05-29
AU2021376584A1 (en) 2023-06-29
EP4240331B1 (en) 2026-04-29
WO2022094816A1 (en) 2022-05-12
UY39503A (es) 2022-05-31
KR20230104226A (ko) 2023-07-07
TW202233178A (zh) 2022-09-01
JP2023548348A (ja) 2023-11-16
MX2023005219A (es) 2023-07-25
CA3200538A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
DOP2023000084A (es) Formulación sólida
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
JOP20230278A1 (ar) تركيبة صيدلانية للوقاية من التليف أو علاجه
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CN115803328A (zh) 哌嗪-2,3-二酮衍生物及其在医药上的应用
JOP20210230A1 (ar) صياغات صيدلانية
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
JOP20250121A1 (ar) مشتقات ٢-أمينو-n-(٤-أمينو-٣، ٤-ديوكسو-١-(٢-أوكسو بيروليدين-٣-يل)بيوتان-2-يل)بنزاميد كمثبطات بروتياز لعلاج أو الوقاية من عدوي فيروس كورونا
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
MX2026000979A (es) Una forma farmaceutica solida de dosificacion bucodispersable de safinamida
EP4442315A3 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
PH12022550430A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
JPWO2021060425A5 (es)
PL4230209T3 (pl) Kompozycja farmaceutyczna, złożona formulacja farmaceutyczna i zestaw złożonej formulacji do zapobiegania przewlekłemu zapaleniu wątroby typu b lub leczenia takiego zapalenia, z których każde zawiera jako składnik czynny doustny środek przeciwwirusowy i szczepionkę terapeutyczną zawierającą lipopeptyd i adiuwant poli(i:c)
MX2023001599A (es) Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip.
WO2021151442A3 (en) Methotrexate dosage form